Drug Profile


Alternative Names: BY 359

Latest Information Update: 02 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nycomed
  • Class Antiulcers; Imidazoles; Naphthyridines
  • Mechanism of Action Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Gastro-oesophageal reflux

Most Recent Events

  • 31 Oct 2007 Data presented at the 15th United European Gastroenterology Week (UEGW-2007) added to the Peptic Ulcer Disease pharmacodynamics section
  • 25 Oct 2005 This compound is still in active development for Gastro-oesophageal reflux
  • 22 Aug 2002 Phase-II clinical trials in Gastro-oesophageal reflux in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top